Recruitment and retention of urban schoolchildren into a randomized double-blind vitamin D supplementation trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

The researchers describe the successful recruitment and retention of urban schoolchildren into a 6-month randomized, double-blind vitamin D3 supplementation trial.

Why It Was Studied

While rarely used for supplementation trials in the United States, schools present a practical alternative to a clinical setting.

Who Took Part

The age groups tagged for this paper are children and teenagers, both men and women.

Boston-area urban schoolchildren, aged 8-15 years, were recruited in 2011-2012 through classroom and auditorium presentations.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Informed consent forms in five languages were sent home to parents.

Retention methods included regular telephone calls and gift cards for completed study visits.

What Was Measured

The subject headings attached to it are Boston, Dietary Supplements, Feasibility Studies, Patient Selection, Schools, Socioeconomic Factors and Urban Population.

The authors tagged it with the keywords Recruitment, children, randomized controlled trial, retention, school-based intervention and vitamin D.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (Clinical trials (London, England)), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.